Invention Grant
- Patent Title: Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
-
Application No.: US18072501Application Date: 2022-11-30
-
Publication No.: US11884675B2Publication Date: 2024-01-30
- Inventor: Lara C. Czabaniuk , Timothy Hopper , Jonathan B. Houze , Jane Panteleev , Gwenaella Rescourio , Vincent Santora , Haoxuan Wang , Ryan D. White , Alice R. Wong , Yongwei Wu , Maxence Bos , John Mancuso , Ivan Franzoni
- Applicant: AMGEN INC. , Vigil Neuroscience, Inc.
- Applicant Address: US CA Thousand Oaks
- Assignee: AMGEN INC.,VIGIL NEUROSCIENCE, INC
- Current Assignee: AMGEN INC.,VIGIL NEUROSCIENCE, INC
- Current Assignee Address: US CA Thousand Oaks; US MA Cambridge
- Agency: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61P25/28 ; C07D413/14 ; C07D471/04
Abstract:
The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).
This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
Public/Granted literature
- US20230295169A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE Public/Granted day:2023-09-21
Information query
